PHF19通过激活PRC2和广泛H3K27me3结构域形成促进多发性骨髓瘤致瘤性
本研究报道PRC2相关辅因子PHF19是多发性骨髓瘤(MM)致瘤性的关键介导者。PHF19过表达和/或基因组扩增与MM和浆细胞白血病恶性进展相关,并与较差治疗结局相关。机制上,PHF19通过其PRC2相互作用和染色质结合功能维持H3K27me3景观,促进PRC2靶基因沉默,MM细胞对PRC2抑制剂敏感。
要点
- PHF19过表达/扩增与MM恶性进展及不良预后相关。
- PHF19通过PRC2相互作用和染色质结合功能维持H3K27me3广泛结构域。
- MM细胞对PRC2抑制剂敏感,提示PRC2阻断可作为治疗策略。
核心结论
- PHF19通过增强H3K27me3沉积和PRC2基因调控功能促进MM致瘤性,支持PRC2阻断作为MM治疗手段。
研究设计与样本
- 使用多种MM模型进行体外和体内研究,并结合染色质免疫沉淀测序、RNA测序和患者样本数据集分析。
主要发现
- PHF19过表达和/或基因组扩增与MM和浆细胞白血病恶性进展相关,并与较差治疗结局相关。
- PHF19为MM体外和体内肿瘤生长所必需,其致癌效应依赖PRC2相互作用和染色质结合功能。
- PHF19缺失导致广泛H3K27me3结构域丢失,可能源于H3K27me3从CpG岛扩散受损。
- PHF19为PRC2靶基因(包括细胞周期抑制剂和干扰素-JAK-STAT信号基因)的最佳沉默所必需。
关键数值与推荐
- PHF19过表达和/或基因组扩增与MM和浆细胞白血病恶性进展相关,并与较差治疗结局相关。
- PHF19缺失导致广泛H3K27me3结构域丢失。
- MM细胞通常对PRC2抑制剂敏感。
临床怎么用
- PHF19及其调控通路可能作为MM预后相关标志物和PRC2抑制剂治疗的潜在依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulation of polycomb repressive complex 2 (PRC2) promotes oncogenesis partly through its enzymatic function for inducing trimethylation of histone H3 lysine 27 (H3K27me3). However, it remains to be determined how PRC2 activity is regulated in normal and diseased settings. We here report a PRC2-associated cofactor, PHD finger protein 19 (PHF19; also known as polycomb-like 3), as a crucial mediator of tumorigenicity in multiple myeloma (MM). Overexpression and/or genomic amplification of PHF19 is found associated with malignant progression of MM and plasma cell leukemia, correlating to worse treatment outcomes. Using various MM models, we demonstrated a critical requirement of PHF19 for tumor growth in vitro and in vivo. Mechanistically, PHF19-mediated oncogenic effect relies on its PRC2-interacting and chromatin-binding functions. Chromatin immunoprecipitation followed by sequencing profiling showed a critical role for PHF19 in maintaining the H3K27me3 landscape. PHF19 depletion led to loss of broad H3K27me3 domains, possibly due to impaired H3K27me3 spreading from cytosine guanine dinucleotide islands, which is reminiscent to the reported effect of an "onco"-histone mutation, H3K27 to methionine (H3K27M). RNA-sequencing-based transcriptome profiling in MM lines also demonstrated a requirement of PHF19 for optimal silencing of PRC2 targets, which include cell cycle inhibitors and interferon-JAK-STAT signaling genes critically involved in tumor suppression. Correlation studies using patient sample data sets further support a clinical relevance of the PHF19-regulated pathways. Lastly, we show that MM cells are generally sensitive to PRC2 inhibitors. Collectively, this study demonstrates that PHF19 promotes MM tumorigenesis through enhancing H3K27me3 deposition and PRC2's gene-regulatory functions, lending support for PRC2 blockade as a means for MM therapeutics.
引用
- Ren Z, Ahn JH, Liu H, et al. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019. PMID: 31383640. doi:10.1182/blood.2019000578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。